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Japanese encephalitis (JE) virus (JEV) is a member of the fam-
ily Flavivirus, genus Flaviviridae. JEV is an arthropod-borne 
virus (arbovirus) endemic to rural parts of South and South-
east Asia. JE is the most commonly diagnosed encephalitis 
in Asia and is an important cause of disability and death in 
children in this region. Only ~0.1–1% of JEV infections in 
humans results in encephalitis (Halstead and Grosz, 1962). 
The remainder is clinically silent or results in a mild febrile 
illness (Watt and Jongsakul, 2003). The overwhelming ma-
jority of JEV-exposed individuals thus develop long-lasting 
naturally induced adaptive immunity, although this wanes in 
later life (Solomon, 2004).
JEV is a single-stranded, positive sense RNA virus; 
the single 10-kb open reading frame encodes three struc-
tural proteins, envelope (E), premembrane (prM), and core 
(C), and seven nonstructural (NS) proteins designated NS1, 
NS2A, NS2B, NS3, NS4A, NS4B, and NS5 (Sumiyoshi et 
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al., 1987). There are an estimated 68,000 cases of JE annually 
and probably around 17,000 deaths (Campbell et al., 2011). 
Clinical outcomes vary from complete recovery to recov-
ery with neuropsychiatric sequelae to death (Solomon et al., 
2002). The role of the immune response to JEV in determin-
ing whether infection is asymptomatic or results in disease is 
incompletely understood.
Protection by neutralizing antibodies (NAbs) to JEV in 
animal models is well established, whether passively admin-
istered, preformed by immunization, or rapidly developed 
after challenge by a memory response (Konishi et al., 1999; 
Gao et al., 2010; Larena et al., 2011; Van Gessel et al., 2011). 
Higher titers of JEV NAbs correlate with better protection 
(Lubiniecki et al., 1973). Development of JEV NAbs after 
vaccination correlates with protection in humans (Hoke et 
al., 1988), and an anamnestic antibody response is associated 
with a good outcome from disease (Libraty et al., 2002; Win-
ter et al., 2004). Conversely, low JEV antibody levels in serum 
and cerebrospinal fluid (CSF) of patients with JE are associ-
ated with death (Libraty et al., 2002; Solomon et al., 2002).
Cell-mediated immunity to JEV is less well studied. Ob-
servations from animal models suggest that T cells play a sub-
sidiary role in protection from JE but could also contribute 
to immunopathology (Larena et al., 2011). Adoptive transfer 
of primed T cells can protect animals from intracerebral JEV 
challenge (Murali-Krishna et al., 1996), even in the absence 
of antibodies in some cases (Ashok and Rangarajan, 1999).
Lymphocyte responses to JEV have been detected in 
humans for many years (Chaturvedi et al., 1979; Konishi et 
al., 1995). Studies of healthy JEV-exposed residents of en-
demic areas demonstrated CD4+ and CD8+ T cell responses 
to several JEV proteins dominated by NS3, especially amino 
acids 193–324 (Kumar et al., 2004c). In recovered JE pa-
tients, IFN-γ responses to NS3 amino acids 193–324 were 
infrequent and smaller than in healthy JEV-exposed controls, 
despite proliferative responses being preserved (Kumar et al., 
2004b). Low IFN-γ production was associated with poor 
outcome, indicating a role for IFN-γ in recovery from JE. 
However, other cytokine responses and responses to other 
JEV proteins have not been examined in JE patients.
JEV cocirculates with other flaviviruses in much of South 
and Southeast Asia, notably the four serotypes of dengue virus 
(DENV). Prior DENV exposure reduces the severity of JE 
(Edelman et al., 1975; Libraty et al., 2002); however, the effect 
of JEV immunity on subsequent DENV infection is less clear. 
A large study of an inactivated JE vaccine in Thailand showed 
those patients who developed dengue hemorrhagic fever 
(DHF) had lower illness severity scores if they had received 
the JE vaccine, suggesting a beneficial effect (Hoke et al., 1988). 
On the other hand, a later careful prospective study in the same 
location showed that the presence of JEV NAbs at the start of 
the study (in the absence of DENV NAbs) gave a 2.75-fold 
increase in the risk of dengue fever (DF; Anderson et al., 2011).
DENV infection primes broadly cross-reactive T cell 
responses; such responses between DENV serotypes have 
been studied extensively, particularly with reference to DHF 
(Rothman, 2010). Limited data suggest that cross-reactive T 
cell responses between JEV and DENV exist in inactivated 
JE vaccine recipients (Aihara et al., 1998). However, the po-
tential for cross-reactive T cell responses between JEV and 
other flaviviruses after natural infection and their potential for 
protection is not known.
Collectively, the available data suggest that T cell re-
sponses could be protective in human JE; however, no study 
to date has compared responses across the entire length of 
the JEV polyprotein between encephalitis and asymptomatic 
infection. Moreover, many of the published DENV epitopes 
show marked similarity to the corresponding sequences in 
JEV, suggesting that immunological cross-recognition by T 
cells is theoretically possible. Given that prior DENV infec-
tion is protective in JE and DENV infection primes broadly 
cross-reactive T cells, we hypothesized that in regions endemic 
to both viruses, patients who had suffered from JE would have 
memory T cell responses that had less cross-reactivity with 
DENV than healthy JEV-exposed subjects. Therefore, we un-
dertook a study to systematically map JEV epitopes using a 
full-length synthetic peptide library for JEV. We assessed the 
specificity, function, and magnitude of the T cell response 
and measured the degree of T cell receptor cross-reactivity in 
healthy JEV-exposed donors and recovered JE patients.
RES ULTS
Subjects
The study took place in Karnataka State, South India, a 
JE-endemic area. 103 participants were recruited into the 
study (Table 1). 51 were healthy Indian residents of JEV-en-
demic areas, and 39 were recovered JE patients. Healthy 
donors were recruited in Bangalore and at the Vijayanagar 
Institute of Medical Sciences (VIMS), Bellary. Recovered JE 
patients were recruited at VIMS. 35 healthy donors (69%) 
were defined as JEV exposed on the basis of residence in 
a JEV-endemic area during childhood and a positive NAb 
assay. A training cohort of 13 participants was recruited in 
the UK, comprising a mixture of flavivirus-exposed and un-
exposed subjects. Two subjects recruited in the UK reported 
classical dengue illness (one DF and one DHF) with posi-
tive DENV IgM, and one more without diagnostic testing; 
all three had acquired infection in dengue-endemic areas and 
were anti-DENV NAb positive.
T cell responses in healthy JEV-exposed subjects are 
dominated by diverse, highly cross-reactive CD8+ cells
35 JEV NAb (Fig. 1 B)+ healthy South Indian donors were 
screened by ELI SPOT assay or whole blood (WB) intra-
cellular cytokine staining (ICS) for JEV T cell responses. 17 
(49%) showed positive ex vivo IFN-γ assays (Fig.  1, A and 
B). In a subset of 24 subjects tested, 22 (92%) showed pro-
liferative responses (Fig.  1  C). IFN-γ responses were pre-
dominantly directed against NS3, NS4, and NS5 (Fig. 1 A) 
and were modest in size (Fig. 1, B and D), whereas prolifer-
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ative responses recognized all viral proteins (Fig. 1 C). Flow 
cytometric analysis showed that 80% of ex vivo IFN-γ re-
sponses were CD8+ (Fig. 1 D).
Clinical data suggest cross-protection between DENV 
and JEV. Two subjects with documented dengue illness (but 
who were unlikely to have been JEV exposed) and one JEV 
NAb-negative volunteer showed IFN-γ ELI SPOT responses 
to the JEV peptide library (Fig. 1 B, red); no responses were 
detected in healthy DENV- and JEV-unexposed controls (un-
published data). The two subjects reporting dengue were also 
positive for JEV NAbs, though anti-DENV titers were higher, 
consistent with prior DENV infection (JEV 50% plaque re-
duction neutralization titer [PRNT50] 1 in 266 and 1 in 85 
and DENV PRNT50 1 in 4,515 [DENV1] and 1 in 12,413 
[DENV3], respectively). Therefore, we set out to determine 
whether JEV and DENV responses cross react. First, responses 
were mapped by ELI SPOT or by expanding short-term T 
cell lines from donors showing ex vivo responses followed by 
deconvolution of pools in ICS assays. Next, cross-reactivity 
was tested using variant peptides from DENV (and other fla-
viviruses) corresponding to the mapped peptides of JEV.
Using this approach, we first studied two naturally 
JEV-exposed subjects (H001/1 and H008/4) and one re-
porting DF (H001/4) in detail. CD8+ T cell responses were 
identical in size and functional characteristics to peptide se-
quence variants from other flaviviruses (Fig. 2 A [top] and B). 
Table 1. Characteristics of the study participants
 Characteristics Recovered JE patients Healthy, JEV NAb-positive  
Indian controls
Healthy, JEV NAb-negative  
Indian controls
UK cohort
n 39 35 16 13
Median age (range) 13 (1–25) 26 (7–55) 25 (22–55) 26 (23–60)
Sex 22 M, 17 F 24 M, 11 F 10 M, 6 F 7 M, 6 F
Years since JE 6 (0.5–12) NA NA NA
Number tested for DENV NAb 14 14 3 8
DENV NAb positive (any serotype) 14 14 3 3
Dengue illness 0 3 0 4
Residence in a JE-endemic area All All All 1
Travel to a JE-endemic area NA NA NA 8
JE vaccine 0 0 0 6a
Liverpool outcome score 5 24 NA NA NA
4 5
3 7
2 3
The Liverpool outcome score is a five-point score grading recovery from encephalitis in children and adolescents (Lewthwaite et al., 2010a). 5, full recovery; 4, minor disability; 3, moderate 
disability; 2, severe disability; 1, death (not applicable here). 
aSix subjects in the UK cohort received the JE vaccine, four before and two during the study period.
Figure 1. Breadth of the T cell response to peptide pools 
of JEV in JEV-exposed healthy donors. (A) Relative frequency 
of ex vivo IFN-γ responses were measured by ELI SPOT or ICS in 
JEV-exposed healthy donors (n = 35, 29 for ELI SPOT, and 6 for 
ICS). Peptide pools are shown grouped by viral proteins. For a sub-
set of five subjects, ICS and ELI SPOT were performed at least three 
times with consistent results. C, core. E, envelope. (B) Spot-form-
ing cells (SFCs) per million PBMCs were measured by ELI SPOT in 
13 healthy JEV-exposed donors (18 responses, black circles) and 
three DENV-exposed subjects (four responses, red triangles). 
(C) Proliferative responses were measured by CFSE dilution and 
flow cytometry in healthy JEV-exposed donors once per subject. 
Data are relative frequency (n = 24) for CD4+ and CD8+ T cells. (D) 
Based on data from ICS assays, the proportion of the total IFN-γ 
response produced by CD8+ T cells in each healthy JEV-exposed 
donor was calculated. The bar depicts the median. n = 11.
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T cell lines showed similar responses in functional assays for 
whichever peptide was tested (Fig. 2 A, bottom), irrespective 
of which peptide was used to expand the line (Fig. 2 C). Ti-
trations of variant peptides showed responses detectable in the 
nanomolar range and that cross-reactivity was not limited to 
high peptide concentration (Fig. 2, B and C), although there 
was some variation in the efficiency of individual peptides.
We then extended this analysis across the cohort using 
peptides of West Nile virus (WNV; a flavivirus closely related 
to JEV), DENV2, and E, NS1, NS3, and NS5 proteins from 
DENV1, 3, and 4 (see Materials and methods). Once library 
peptides were mapped, the same T cell lines were then tested 
against the equivalent peptides from DENV1–4 and WNV 
based on a ClustalW alignment of the library polyprotein se-
quence (an example is shown in Fig. 2 D). Responses to the 
variant peptides were normalized across different assays by di-
viding the result by the value for JEV peptides in the same assay, 
with a cross-reactivity index of 1 indicating an equal response 
to JEV and variant peptides. In five subjects, cross-reactive 
responses tested both ex vivo and on T cell lines showed good 
agreement (Fig. 2 E). Next, we studied 10 healthy JEV-exposed 
donors in whom 15 epitopes were mapped. In all but three, re-
sponses were highly cross-reactive (Fig. 2 F) and were not sig-
nificantly different from the hypothetical value of 1 (indicating 
equivalent responses) by a Wilcoxon signed rank test. 8 out of 
the 10 donors showed responses that recognized peptides from 
at least two other flaviviruses (often more) as efficiently as JEV.
Cross-reactivity was confirmed by dual tetramer stain-
ing between the JEV epitope and three variant epitopes from 
WNV, DENV1, and DENV2/3 (Fig. 2 G), at least in one in-
dividual. Cross-reactivity occurred at the single cell level with 
apparently equal affinity (Fig. 2 H). Finally, to determine past 
exposure to DENV, PRNT50 to DENV1–4 was measured in 
those subjects who had cross-reactivity assays performed; the 
cohort was extensively DENV exposed (Fig. 2 I).
Overall, these experiments confirmed clear JEV-specific 
T cell memory responses in JEV NAb-positive subjects from a 
JE-endemic area. These responses were predominantly CD8+, 
highly cross-reactive among flaviviruses, and mostly targeted 
NS proteins, including in donors with clear DENV exposure.
CD8+ T cell responses in healthy JEV-exposed subjects are 
polyfunctional and show a cytotoxic phenotype
We next addressed the functionality of these responses. We 
asked whether cytokines were cosecreted by JEV-specific T 
cells using WB ICS assays; example flow cytometry data are 
shown in Fig. 3 A. The CD8+ T cell response was dominated 
by IFN-γ+/TNF-α+/MIP-1β+ and IFN-γ+/TNF-α+ cells 
(Fig. 3 B). Overall, 75% of the responding cells made more than 
one cytokine. The small number of CD4+ T cell responses pre-
cluded this analysis for this population; CD4+ T cell responses 
were smaller as well as less frequently detected (Fig. 3 C).
To address the production of other cytokines, bead 
array assays were performed in a subset of 13 donors on day 2 
and day 5 supernatants from proliferation assays showing the 
largest responses, which were often different pools from the 
ex vivo IFN-γ assays (Fig. 3 D, data for day 5). This showed 
some evidence of more diverse cellular responses with release 
of IL-10 (the cytokine most frequently detected in these as-
says) in 11 (85%) of the donors (Fig. 3, D and E); IL-4 and 
IL-13 were also detected, but in much smaller amounts and 
less frequently. Other T cell–derived cytokines and chemo-
kines were detected infrequently; five subjects (39%) made 
either CCL3 or CCL5 responses, and only two subjects (15%) 
made IL-17A (Fig. 3 E).
In selected individuals, where resampling was possible 
after CD8+ T cell responses were mapped, the cytotoxic ca-
pacity of these cells was studied in more detail. JEV-specific 
CD8+ T cell responses degranulated in response to peptide 
stimulation (Fig.  4  A), and degranulation responses were 
cross-reactive (Fig.  4, A–C). Responses were detectable to 
at least 10 nM of peptide ex vivo, indicating that they are 
likely to be functional in vivo (Fig. 4 C). Responding cells 
expressed perforin and granzyme B (Fig. 4, D–F) consistent 
with killing capacity. To confirm these results, short-term T 
cell lines were expanded to responding peptides; these, too, 
degranulated (Fig.  4  G) and were cross-reactive between 
JEV and DENV (Fig. 4 H). Cross-reactive degranulation re-
sponses were equivalent in overall functionality between JEV 
and DENV, with 55–60% of responding cells degranulating in 
both cases (Fig. 4 I). Finally, cross-reactive CD8+ T cell lines 
were able to kill peptide-loaded cells, whether expanded to 
JEV or DENV peptides (Fig. 4 J).
Screening for T cell responses in convalescent JE patients
We next addressed T cell responses in recovered JE patients. 
39 recovered JE patients were screened by ELI SPOT or WB 
ICS; 28 (72%) showed ex vivo IFN-γ responses. Sample flow 
cytometry data are shown in Fig. 5 A. Ex vivo IFN-γ responses 
targeted all JEV proteins (Fig.  5 B), with slightly more re-
sponses against the C/prM and NS1/NS2 pools. Around 80% 
of the IFN-γ response came from CD4+ T cells (Fig. 5 C), and 
several donors showed exclusively CD4+ responses. Prolifera-
tive responses were similarly distributed among JEV proteins 
(Fig. 5, D and E). Responding peptides were mapped using 
short-term T cell lines using the same strategy as the healthy 
JEV-exposed donors, and 14 peptides from seven recov-
ered patients were tested in cross-reactivity assays (Fig. 5 F). 
Mapped responses in recovered JE patients were mostly JEV 
specific and showed a cross-reactivity index significantly dif-
ferent from the hypothetical value of 1 (indicating equivalent 
responses) by Wilcoxon signed rank test in all cases except 
DENV1, which approached significance despite fewer variant 
peptides tested. Importantly, NAbs to DENV were present 
in all the recovered JE patients with peptides mapped and 
cross-reactivity assays performed (Fig. 5 G and Table 1), sug-
gesting the lack of cross-reactivity in recovered JE patients is 
not a result of lack of DENV exposure. In the same subset, 
JEV NAb titers were also tested and showed no difference 
between good outcome and poor groups (Fig. 5 H).
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Figure 2. CD8+ T cell responses are highly flavivirus cross-reactive in healthy JEV-exposed donors. (A) ICS assays were used to detect IFN-γ+/TNF-α+ 
cells from healthy JEV-exposed donor H008/4. Example flow cytometry data from an ex vivo assay (top) and a short-term T cell line (bottom) show responses 
to variant peptides of JEV NS5 MTT EDM LQVW, gated on live, CD3+, and CD8+ cells, representative of three experiments. Similar results were obtained with 
T cells in Japanese encephalitis | Turtle et al.1336
A polyfunctional, IFN-γ–dominated CD4+ T cell 
response correlates with better clinical outcome in 
convalescent JE patients
JE patients were categorized into good outcome (complete 
recovery with no neurological deficit; Liverpool outcome 
score of 5) or poor outcome (incomplete recovery; Liverpool 
outcome score of 2–4 or abnormal neurological examina-
tion; see Materials and methods). There was no difference in 
targeting of viral proteins or the proportion of the response 
expressed by CD4+ T cells when analyzed by outcome (un-
published data). IFN-γ ICS responses, however, were larger in 
patients with a good outcome (Fig. 6 A). TNF-α production 
was equivalent between the two groups (Fig. 6 B) but was 
derived mostly from TNF-α single positive cells in those with 
poor outcome (Fig. 6 C). Complete recovery was strongly as-
sociated with a polyfunctional IFN-γ+/IL2+/TNF-α+ CD4+ 
T cell response, indicating that a poor quality memory re-
sponse, which is proinflammatory but lacking in antiviral/
helper capacity, is associated with recovery from JE with long-
term neurological damage.
To explore cytokine production further, in a subgroup 
of 11 patients, secreted cytokine responses were assayed from 
the day 2 and day 5 supernatants of proliferation assays as for 
the healthy JEV-exposed group (Fig. 6 D, data for day 5). In 
these assays, across both time points, IL-10 and IL-13 were 
detected in several patients from both groups (Fig. 6, D and E), 
and proinflammatory TNF-α responses were frequent. Sim-
ilar to the healthy group, other T cell–derived cytokine and 
chemokine responses were rare. Three subjects made CCL3 or 
CCL5 responses, and three made IL-17A. Looking specifically 
at CD8+ T cell responses in recovered JE patients by WB ICS, 
these were mostly polyfunctional and characterized by IFN-γ+/
TNF-α+/MIP-1β+ and IFN-γ+/TNF-α+ cells (Fig. 6 F).
Importantly, all the patients were sampled at least 6 mo 
after acute illness, by which time most recovery is expected 
to have occurred. Time from illness to sampling was the same 
in both groups (Fig.  6 G), indicating that this variable did 
not confound the results. Interestingly, the observed defect in 
CD4+ T cell cytokine production was not apparent in pro-
liferative responses, which were equal in magnitude between 
the two groups; CD8+ proliferative responses were slightly 
larger in those with poor outcome (Fig. 5 E). Overall, these 
results indicated that T cell responses in patients who have re-
covered from JE were predominantly CD4+ and JEV specific. 
Smaller IFN-γ responses in conjunction with poor quality, 
proinflammatory (TNF-α+) CD4+ responses were associ-
ated with a poor outcome.
T cell responses are differentially targeted in JE 
patients and healthy donors
During screening, ex vivo IFN-γ responses in healthy JEV- 
exposed donors were directed mostly at NS3, NS4, and NS5 
(Fig. 1 A), whereas recovered JE patients responded to all JEV 
proteins (Fig. 5 B). Mapped peptides were plotted according to 
their location in the JEV polyprotein for healthy, JEV-exposed 
donors (Fig. 7 A), recovered JE patients (Fig. 7 B), and two 
UK participants reporting dengue illness (Fig. 7 C). Sequences 
of all the JEV peptides identified are in Table 2, and the vari-
ant peptides showing responses in cross-reactivity assays are 
shown in Table 3. Almost all the mapped responses in struc-
tural proteins were identified in JE patients, and one healthy 
JEV-exposed donor showed a CD4+ response to the E protein 
of JEV (Fig. 7, A and B; and Table 2). In contrast, the responses 
in healthy JEV-exposed donors were focused on NS3 and NS5, 
and only one peptide was successfully mapped in NS3 in a 
JE patient. This was despite multiple attempts at expanding T 
cell lines to NS3 in vitro, which failed to produce responses in 
all except one individual. The two subjects reporting dengue 
illness showed similar findings to the healthy JEV-exposed 
donors (Fig. 7 C). The mean Shannon entropy (H index) of 
DENV4 and WNV peptides (not depicted). Axes are log10 fluorescence units. (B) IFN-γ responses to peptide titrations of the same NS5 peptides as in A and 
WNV peptide MTT EDM LEVW were measured by ex vivo ELI SPOT. The results are representative of two independent experiments. SFC, spot-forming cell. 
(C) Cytokine (IFN-γ+, TNF-α+, or MIP-1β+ in any combination) responses to NS3 peptide titrations of JEV, DENV1–4, and yellow fever virus (YFV) presented 
on a B cell line matched for HLA B*08:01 were measured by ICS. Responding cells were CD8+ T cell lines (TCL) from a subject reporting dengue illness and 
yellow fever vaccination but not JEV exposure (H001/4), expanded with JEV (left) or DENV (right) peptides, each assayed against all three peptides. The black 
diamonds indicate peptides with no B cell line. Open squares indicate a peptide-pulsed HLA-mismatched B cell line. Peptide titrations by ex vivo ELI SPOT 
or ICS gave similar results, and expansion of T cell lines from two further independent samples showed equal cross-reactivity. (D) IFN-γ+/TNF-α+ cells of 
a CD8+ T cell line from healthy JEV-exposed donor H007/3 were measured by ICS to a JEV NS5 peptide and the DENV variant peptides indicated, showing 
epitope conservation in variant peptides. The same experiment was performed twice ex vivo with similar results. (E) Cross-reactivity of ex vivo responses 
and short-term T cell lines were measured by ICS. Cross-reactivity index (variant response/JEV response from the same assay) between JEV and DENV1–4/
WNV in five subjects of ex vivo measurements correlated with T cell lines (Spearman’s R = 0.62; P = 0.002). Ex vivo assays were performed at least twice in 
all donors except one with similar results. (F) Cross-reactivity of short-term T cell lines expanded with JEV peptides with WNV, and DENV1–4 measured by 
ICS. Data are cross-reactivity indices as in E of all T cell responses identified in healthy JEV-exposed donors. Wilcoxon signed rank tests showed no significant 
differences from a hypothetical value of 1 (indicating an equal response to JEV and variant peptides). In two subjects, these assays were repeated three 
times with good agreement. (G) CD8+ T cells from donor H008/4 were stained with JEV peptide–HLA class I tetramers (x axis) and variant peptide tetramers 
(y axis) and analyzed by flow cytometry. Data are representative of two independent experiments. (H) CD8+ T cells were tetramer stained and analyzed as in 
G. Titrations of three different tetramers are shown: JEV (MTT EDM LQVW), WNV (MTT EDM LEVW), and DENV2+3 (MTT EDM LTVW; common epitope). Data are 
median fluorescence intensity (left) and percentage of CD8+ T cells stained (right). Repeating this experiment using a short-term T cell line expanded with 
JEV peptides gave similar results. (I) Neutralizing antibodies against JEV and all four DENV serotypes were measured by PRNT50. The bars depict the median. 
Four subjects had some assays repeated with similar results.
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Indian isolates of JEV and DENV corresponding to the posi-
tion of JEV peptides eliciting T cell responses in recovered JE 
patients was significantly greater than in healthy JEV-exposed 
donors (P = 0.0003; Fig. 7 F), indicating that heathy donors 
target conserved regions of the flavivirus polyprotein.
The absence of T cell responses in NS1 in the healthy 
JEV-exposed donors could not be explained by a lack of po-
tential HLA-binding motifs. The HLArestrictor server (Erup 
Larsen et al., 2011) identified 122 HLA class I–binding mo-
tifs for the alleles ranked strong binder, with a predicted ac-
Figure 3. Function of T cell responses to peptide pools of JEV in healthy JEV-exposed donors. (A) WB ICS assays were used to measure cytokine+ 
cells from 11 healthy JEV-exposed donors. Example data from a WB ICS experiment (donor H014/3) are shown. Axes are log10 fluorescence units. (Top) 
IFN-γ versus TNF-α. (Bottom) IFN-γ versus MIP-1β. (B) WB ICS data were analyzed using SPI CE software for 10 donors; 1 donor did not have the full flow 
cytometry panel performed. The bars indicate median and interquartile range (IQR). Pie slices indicate the fraction of response of the group that expresses 
cytokines four, three, two, and one in any combination. (C) Magnitude of CD4+ and CD8+ WB ICS IFN-γ+/TNF-α+ responses in healthy JEV-exposed donors 
measured by ICS (n = 11, 15 CD8+ responses and 3 CD4+ responses). (D) Secreted cytokine concentrations were measured by bead array from 12 healthy 
JEV-exposed donors after 5 d of stimulation with JEV peptide pools. The heat map depicts log10-transformed picograms/milliliter. Some subjects had more 
than one peptide pool assayed. Data are depicted after subtraction of values obtained from unstimulated cells. This experiment was performed once. 
(E) Relative frequency of secreted cytokine responses from the same data as in D after 2 and 5 d of stimulation with JEV peptide pools. Subjects were con-
sidered positive if any pool was positive at either time point.
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Figure 4. CD8+ T cell responses from JEV-exposed donors show a cytotoxic phenotype. (A) Degranulation of CD8+ T cells in response to JEV and 
DENV variant peptides was measured by CD107a staining/flow cytometry. Representative data are from one of two experiments in a healthy JEV-exposed 
donor (H008/4). (B) Degranulation responses to variant flavivirus peptides were measured as in A in naturally JEV-exposed subjects (n = 7; six healthy and 
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curacy of >80%. A more limited analysis of the HLA class II 
DRB1 alleles 03:01, 04:01, 07:01, 11:01, and 15:01 using 
SYF PET HI (Rammensee et al., 1999) showed 197 15-mer 
peptides with scores ≥20.
Few peptides were identified in more than one individ-
ual despite overlap of HLA alleles across the cohort (Table 2). 
One exception was peptide TMA MTD TTP FGQ QRV FK at 
position 2,869–2,885 of the viral polyprotein (NS5 amino 
acids 342–358), which showed CD8+ T cell responses in 
three healthy JEV-exposed donors and one DENV-exposed 
donor. This corresponds to a highly conserved 20–amino 
acid segment that is nearly identical across all the medically 
important mosquito-borne flaviviruses, visible as a trough in 
Shannon entropy (H index) in NS5 (Fig. 7 D). In our study, 
three healthy HLA A*68:01–positive JEV-exposed donors 
who recognized JEV NS5 342–358 also recognized DENV 
peptides that were truncated for the C-terminal three amino 
acids (Fig. 2 D), suggesting they were recognizing DTT PFG 
QQR, previously described as one of the most immunogenic 
DENV CD8+ T cell epitopes out of 408 identified (Weiskopf 
et al., 2013). In a fourth DENV-exposed, HLA B*35:01–pos-
itive subject (H010/4), the JEV NS5 342–358 response was 
mapped to TPF GQQ RVF (Table 2), also previously shown to 
be presented by this allele (Rivino et al., 2013).
These data suggest that T cell responses from recovered 
JE patients target JEV-specific regions that are less conserved 
among flaviviruses (high H index). Healthy JEV-exposed 
donors made responses against conserved regions that were 
highly cross-reactive among different flaviviruses (Fig. 2 F).
DIS CUS SION
In this study, we have presented data showing that, across the 
entire JEV polyprotein, memory T cell responses in healthy 
JEV-exposed donors are (1) predominantly directed against 
NS3, NS4, and NS5, (2) are CD8+, and (3) cross react ex-
tensively between flaviviruses. Recovered JE patients, on the 
other hand, mount mostly JEV-specific CD4+ T cell responses 
and target epitopes predominantly within the JEV structural 
proteins and the secreted protein NS1. Among the recovered 
JE patients, the quality of the ex vivo CD4+ T cell response 
was associated with outcome; in individuals with poor out-
come, the presence of a significant TNF-α+-only CD4+ T cell 
population suggests a potential mechanism whereby T cells 
might contribute to damaging inflammation in JE. These data 
are compatible with the notion, supported by animal studies 
(Larena et al., 2011, 2013), that T cells may play a role both 
in protection and immunopathology in JE. In addition, this 
study describes the first polyfunctional T cell responses to 
JEV, the first minimal epitopes of JEV in humans, and the first 
demonstration of cytotoxic CD8+ T cell responses to JEV in 
naturally exposed individuals.
Antiviral T cells exhibiting multiple functions are well 
described after many viral infections and have been observed 
after infection or vaccination with several flaviviruses (Akondy 
et al., 2009; Piazza et al., 2010; Friberg et al., 2011b). In this 
study, we have described polyfunctional T cell responses to 
JEV in both CD4+ and CD8+ subsets and found that the 
quality of the CD4+ T cell response was the factor most 
strongly associated with complete recovery from JE. Evidence 
for the protective capacity of polyfunctional T cell responses 
in humans is largely correlative (Betts et al., 2006), as is the 
case here. On average, >50% of the responding cells expressed 
two or more cytokines, and the subjects in this study were 
sampled a median ≥6 yr after the viral encounter. Therefore, 
these responses likely reflect a long-lived stable memory pop-
ulation rather than newly responding or terminally differenti-
ated single cytokine-positive cells (Seder et al., 2008).
In a subgroup of subjects, CD8+ T cell degranulation 
responses were studied. Sampling limitations meant we could 
not test these responses in the whole cohort, but in all the 
subjects tested, CD8+ T cells degranulated in response to 
JEV peptides in the 10-nM range. Degranulation and per-
forin and granzyme B expression correlate closely with the 
ability to kill (Betts et al., 2003; Pardo et al., 2004), which 
we have confirmed using peptide-loaded cells. These cyto-
toxic responses also cross react between JEV and DENV; in 
other words, a DENV-primed cell could in principle kill a 
JEV-infected target or vice versa. Killing of cells expressing 
one recovered JE patient) and subjects reporting dengue illness (n = 2). Dengue illness and recovered JE are indicated by open, red triangles and purple 
circles, respectively. (C) Degranulation responses were measured as in A to titrations of JEV and DENV variant peptides in two healthy JEV-exposed donors 
(left, H001/1; middle, H008/4) and a subject reporting dengue illness (right, H001/4). (D and E) JEV-specific CD8+ T cells were identified by IFN-γ ICS and 
costained for perforin (D) and granzyme B (E). Representative data from one (perforin, JE054/2; granzyme B, H008/4) of four subjects are shown. (F) IFN-γ/
granzyme B+ and CD107a/granzyme B+ double-positive CD8+ T cells were detected in the same experiments as in D and E in one healthy JEV-exposed and 
two dengue-exposed donors in response to all peptides tested: four JEV and two DENV peptides. (G) Degranulation of a short-term T cell line from a healthy 
JEV-exposed donor (H007/2) in response to JEV and DENV variant peptides measured as in A and representative of five donors tested. (H) Data from the same 
experiment as in G showing cross-reactivity for DENV peptides. Cross-reactivity was observed in two independent experiments, and one included CD107a 
staining. (I) CD8+ T cell IFN-γ, TNF-α, MIP-1β, and CD107a responses were measured by ICS and analyzed using SPI CE. Six healthy JEV-exposed donors (seven 
JEV responses), four of whom had variant DENV peptides tested (15 DENV peptides), were included. In two subjects, repeat experiments showed similar 
results. The bars indicate median and IQR, and pie slices indicate the fraction of response showing four, three, two, and one function in any combination. (J) 
Peptide-pulsed, CFSE-labeled, HLA-matched targets were incubated with CD8+ T cell line effector cells, and the percent specific killing was measured by flow 
cytometry in response to JEV and DENV peptides. The peptides used were: donor H001/4 (DVM CHA TL [JEV] and DLM CHA TF [DENV]) and donor H008/4 (MTT 
EDM LQVW [JEV], MTT EDM LSVW [DENV1], and MTT EDM LTVW [DENV2/3]). Diamonds indicate lines expanded with JEV peptide, and squares indicate DENV 
peptide. Assays were performed in duplicate for each T cell line/peptide pair. Error bars represent standard error of the mean.
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Figure 5. Breadth of the T cell response to JEV peptide pools in recovered JE patients. (A) WB ICS assays were used to measure cytokine+ cells in 
recovered JE patients. Example flow cytometry data from four patients are shown. Axes are log10 fluorescence units. (Top) CD8+ responses, IFN-γ versus 
TNF-α (left) and IFN-γ versus MIP-1β (right). (Bottom) CD4+ responses, IFN-γ versus TNF-α (left) and IL2 versus TNF-α (right). (B) Ex vivo IFN-γ responses 
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pox virus–vectored JEV prM/E/NS1 proteins has previously 
been demonstrated for CD4+ T cell clones and CD8+ short-
term T cell lines expanded from PBMCs from JE-vaccinated 
subjects, rather than natural JEV exposure (Aihara et al., 1998; 
Konishi et al., 1998). Although we have not shown killing of 
virally infected target cells (itself a surrogate marker of protec-
tion), the data presented here make it highly likely that these 
responses would be capable of killing JEV-infected cells. T cell 
killing of JEV-infected cells, to our knowledge, has only been 
shown for murine and never for human cytotoxic T lympho-
cytes (Murali-Krishna et al., 1994).
Previous work in the same location found a higher fre-
quency of responses to NS3 (Kumar et al., 2004a,b), likely 
accounted for by the time interval between exposure and 
testing. The patients in our study were sampled on average 
6 yr after JE, whereas in the studies by Kumar et al. (2004b), 
they were sampled ~6 mo after disease. In the case of DENV, 
when patients are sampled 2 wk after illness, the frequency of 
responses to NS3 reported is as high as 90% (Duangchinda 
et al., 2010). In recovered JE patients, IFN-γ ELI SPOT re-
sponses to NS3 were small (unpublished data), and repeated 
attempts at in vitro expansion of responding T cells to NS3 
consistently failed to produce responses in IFN-γ/TNF-α 
ICS assays. Collectively, our results are consistent with earlier 
findings that JE patients had defective IFN-γ but preserved 
proliferation responses to JEV NS3 amino acids 193–324 
(Kumar et al., 2004b). Now, we have also shown that reduc-
tion in IFN-γ is a general phenomenon associated with a 
poor outcome from JE and occurs in response to all JEV 
proteins, not only NS3, increasing the likelihood that this is 
a biologically relevant result. In addition, we have extended 
these findings to show that an unbalanced CD4+ T cell re-
sponse characterized by proinflammatory TNF-α production, 
in the absence of sufficient additional helper/antiviral IL2 and 
IFN-γ, is strongly associated with a poor outcome from JE.
We observed a striking degree of cross-reactivity in 
the NS protein–specific short-term CD8+ T cell lines from 
healthy JEV-exposed donors. The mean Shannon entropy 
of sequences recognized by this group was low, indicating 
they were highly conserved. A recent study on dengue also 
found that the majority of conserved CD8+ T cell epitopes 
are found in the NS proteins (Weiskopf et al., 2015). Short-
term T cell lines from some healthy donors in our study rec-
ognized peptides from flaviviruses for which the chance of 
exposure was extremely remote, such as tick-borne encepha-
litis virus and St. Louis encephalitis virus (unpublished data), 
and some sequences were in common with geographically 
diverse viruses such as Murray Valley encephalitis virus and 
Zika virus, suggesting that this phenomenon goes beyond 
simply exposure and is largely accounted for by selective tar-
geting of conserved regions. The dominant responses in re-
covered JE patients, however, cross reacted much less with 
variant peptides from DENV and WNV. DENV NAb assays 
revealed this was not simply caused by a lack of exposure. 
CD4+ T cells dominated the responses in recovered JE pa-
tients, and this cannot account for the lack of cross-reactiv-
ity because CD4+ T cells are known to mount cross-reactive 
responses to flaviviruses (Kurane et al., 1991; Aihara et al., 
1998). Although the cross-reactivity of T cell responses ap-
peared to differ between healthy JEV-exposed donors and re-
covered patients, the retrospective nature of this study and the 
likely difference in time between exposure and sampling for 
these different groups limit our ability to assign a protective 
role to these responses.
Both serotype-specific and serotype cross-reactive T cell 
responses are readily detectable after a single DENV infection 
(Friberg et al., 2011a), and over subsequent DENV expo-
sures, the response may be skewed toward more conserved 
epitopes (Weiskopf et al., 2013). The exposure to DENV 
and the highly cross-reactive T cell responses in the healthy 
JEV-exposed donors in this study are consistent with these 
findings and suggest this phenomenon is not restricted to 
DENV. Given the protective effect of DENV on JEV (Edel-
man et al., 1975), one possibility is that exposure to DENV 
primes JEV cross-reactive T cell responses. Although there are 
well described examples of pathology mediated by DENV 
cross-reactive T cells (Mongkolsapaya et al., 2003), not all 
studies on dengue have confirmed the relationship between 
cross-reactive T cells and disease (Friberg et al., 2011a), and 
some observations imply a protective role for cross-reactive 
memory T cells (Hatch et al., 2011; Weiskopf et al., 2013). 
Similarly, animal models of sequential T cell priming and 
from 39 recovered JE patients were measured by ELI SPOT (n = 17) or ICS (n = 22), and relative frequency of responses to each peptide pool was calculated. 
(C) The relative proportion of the cytokine response produced by CD4+ T cells in individual patients was measured by ICS in the same experiments as in A 
and B. The bar depicts the median. (D) Proliferation responses were measured by CFSE dilution and flow cytometry in 18 recovered JE patients of whom 15 
showed responses. The relative frequency for CD4+ T cells and CD8+ T cells is shown. (E) Proliferative responses from the same experiments as in D were equal 
in size between good outcome and poor outcome for CD4+ cells (25 responses in eight patients with good outcome and 13 responses in four patients with 
poor outcome; Mann Whitney U test); CD8+ responses were larger in poor outcome (23 responses in eight patients with good outcome and 17 responses 
in six patients with poor outcome). The bars depict the median and IQR, whiskers are 1.5 × IQR, and outliers are shown as points. (F) Cross-reactivity of 
short-term T cell lines expanded with JEV peptides with DENV1–4 and WNV were measured by ICS. Data are cross-reactivity indices (as in Fig. 2 E) of 14 T 
cell responses identified in seven recovered JE patients. Wilcoxon signed rank tests showed significant differences from a hypothetical value of 1 (i.e., the 
response to JEV and variant peptides was not equivalent) for all viruses except DENV1. Number of peptides tested: WNV = 13; DENV1 = 9; DENV2 = 14; 
DENV3 = 11; DENV4 = 11. (G) NAbs against JEV and all four DENV serotypes were measured by PRNT50. The bars depict the median. Assays were generally 
performed once per person, and nine subjects had some assays repeated with similar results. (H) JEV PRNT50 were the same in JE patients with good (n = 7) 
and poor (n = 9) outcome (Mann Whitney U test). The bars depict the median and IQR. C, core protein. E, envelope protein.
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Figure 6. T cell cytokine responses to JEV peptide pools in recovered JE patients. (A–C) Recovered JE patients showing CD4+ T cell responses were 
categorized into good outcome (complete recovery; n = 16) and poor outcome (recovery with residual neurological deficit/disability >6 mo after disease; 
n = 11). Cytokine responses were measured by WB ICS once per subject. 30 responses were detected in the good outcome group and 22 responses in the 
poor outcome group. (A) IFN-γ responses were smaller in those with poor outcome (Mann Whitey U test). (B) TNF-α responses showed no difference with 
outcome (Mann Whitey U test). (C) CD4+ T cell responses were analyzed using SPI CE according to the outcome from JE. Patients with poor outcome had 
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challenge can show either impaired or enhanced protection 
(Welsh et al., 2010). JE pathogenesis is distinct from some 
other viral infections in that viraemia is typically very low 
and often clinically inapparent; therefore, an early, modestly 
sized, cross-reactive CD8+ T cell response in the periphery 
may prevent dissemination to the central nervous system and 
limit the virus to a compartment where it is not particularly 
pathogenic. The retrospective nature of this study means we 
are unable to address this question directly, but this could be 
the subject of future prospective studies.
There are several possible reasons for the limited fla-
vivirus cross-reactive T cell responses seen in recovered JE 
patients, even years after disease and despite DENV expo-
sure. There may be intrinsically pathogenic responses in the 
context of disease that are different from those in health, and 
age at exposure or variation in innate immunity may affect 
the character of responses. Also, the order of priming may af-
fect the cross-reactivity of T cell responses. Support for this is 
found in epidemiological observations that DENV infection 
is at least partially protective against JE (Edelman et al., 1975; 
Libraty et al., 2002) and that JEV NAbs (but not vaccination) 
has a detrimental effect on DENV (Anderson et al., 2011). 
However, a weakness of our study (common to many) is that 
we cannot determine the order in which different flaviviruses 
were encountered and therefore cannot provide direct evi-
dence that JEV priming modifies DENV responses. Future 
prospective studies could address this question and investigate 
differences in the T cell response as a potential mechanism.
Ex vivo responses in recovered JE patients against the 
structural proteins and the pool containing NS1 were fre-
quently observed but were rare in the healthy JEV-exposed 
donors. It is hypothesized based on observations in DF that 
structural proteins and the secreted protein NS1 interact with 
B cells and elicit CD4+ responses, whereas the remaining 
NS proteins elicit mostly CD8+ T cell responses (Rivino et 
al., 2013), consistent with what we have seen in this study. 
The reasons underlying the absence of responses to NS1 in 
the healthy JEV-exposed donors are not clear, but previous 
work in this region identified T cell responses against NS1 in 
healthy children (Kumar et al., 2004a), so anti-NS1 responses 
are likely not intrinsically pathogenic.
Although the dominant responses mapped in recovered 
JE patients were directed against less conserved viral proteins, 
we nevertheless identified several IFN-γ responses against 
NS3, NS4, and NS5. One CD8+ T cell response from a re-
covered JE patient (JE098/2) targeted a conserved epitope 
(ELG EAA AIF MTA TPP; NS3 306–320), which showed a 
cross-reactive response in subject H013/3 (these two sub-
jects shared HLA 02:01 and B40:01, as well as being closely 
matched at B35:01 and B35:03; Table 2). This response was 
not further tested in JE098/2 (because of insufficient cells), 
but it is likely that this response would have been cross-re-
active. Although the predominance of JEV-specific responses 
in recovered JE patients is likely explained by variation in 
amino acid sequences between JEV and DENV, in some cases, 
single amino acid changes (aside from anchor residues) had 
very profound effects on responses. For example, changing 
Ala at position 5 of GEA AAI FMT to Gly completely abol-
ished CD8+ T cell recognition in donor H013/3. In donor 
JE054/2, changing Leu to Ile (a very modest alteration) at 
position 12 of peptide AIS GDD CVV KPL DDRF made no 
difference, whereas changing Asp to Glu (also similar amino 
acids) at position 14 eliminated the CD8+ T cell response. 
On the other hand, two amino acid changes from the HLA 
B*08:01–restricted epitope DLM CHA TF (DENV) to DVM 
CHA TL (JEV) gave rise to identical CD8+ T cell responses 
in donor H001/4 (who reported dengue illness), and a wide 
range of single amino acid variants from Gln at position 8 of 
the HLA B*58:01–restricted epitope MTT EDM LQVW (to 
Ser, Thr, Asp, or Glu) were also recognized by CD8+ T cells in 
donor H008/4. Therefore, the number of amino acid variants 
alone cannot explain the variation in cross-reactive responses 
seen here, and the reasons for this remain to be determined.
A limitation of our study is that the healthy JEV-ex-
posed donors were older than the recovered JE patients. 
Practically, it is difficult to draw blood from children who 
have not been ill in this setting. Nevertheless, both groups 
were well matched for viral exposure and likely were ex-
posed to JEV years earlier with ongoing exposure year to 
year, and we are not drawing direct comparisons between the 
two groups. Our within-group comparison of the outcome 
from JE does not suffer from this limitation. Ideally, the two 
groups should be matched for the time elapsed since first ex-
posure to JEV, although within groups, we could not observe 
a signal indicating a change in responsiveness of cross-reac-
tivity over time/age (unpublished data). The optimum way 
to address this question would be using a prospective study 
design, but given the high rate of asymptomatic JEV infec-
fewer polyfunctional cells (SPI CE pie comparison, 10,000 replicates), with the difference largely accounted for by fewer IFN-γ+/TNF-α+/IL2+ cells (P = 0.001 
for a Mann Whitney U test) and more TNF-α+ cells (P < 0.0001). The data were analyzed for individual responses; summing by subjects retained the strong 
significance of the result. (D) Secreted cytokine concentrations were measured by bead array from 11 recovered JE patients after 5 d of stimulation with JEV 
peptide pools. The heat map depicts log10-transformed picograms/milliliter. Some subjects had more than one peptide pool assayed. Data are depicted after 
subtraction of values from unstimulated cells and are displayed according to outcome from JE. (Top) Good outcome, n = 7. (Bottom) Poor outcome, n = 4. 
This experiment was performed once. C, core protein. prM, pre-membrane protein. E, envelope protein. NS, non-structural protein. (E) Relative frequency 
of secreted cytokine responses from the same experiments as in D after 2 and 5 d of stimulation with JEV peptide pools. Subjects were considered positive 
if any pool was positive at either time point. (F) CD8+ T cell responses from recovered JE patients were assayed once per subject by WB ICS (n = 14; 18 
responses) and analyzed using SPI CE. (G) There was no difference in years since admission with clinical JE and sampling for this study between the good 
and poor outcome groups (Mann Whitney U test). Good outcome, n = 22. Poor outcome, n = 16.
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tion, relatively low incidence of JE, and existence of many 
other conditions that are hard to differentiate from JE, such a 
study would be impractical.
A second shortcoming is the small number of subjects 
with peptide mapping and cross-reactive T cell response data, 
despite the screening of larger numbers. Although the clinical 
setting introduces some limitations, our data demonstrate a 
clear lack of cross-reactive responses in recovered JE patients. 
A technical concern of our cross-reactivity experiments was 
that these were not conducted on optimally defined peptides, 
as optimal T cell epitopes located within a larger peptide can 
affect detection of the response (Draenert et al., 2004). The 
need to deconvolute the peptide pools in quick succession 
using single T cell lines, making maximal use of scarce samples, 
precluded minimal epitope mapping and HLA restriction in 
each case. Despite this, cross-reactive responses were readily 
detectable using library peptides. Because of the closed-ended 
nature of the HLA class I peptide-binding groove, this would 
reduce detection of cross-reactive CD8+ T cell responses 
more than CD4+, the converse of what we have observed. 
Lastly, we justified the use of short-term T cell lines by show-
ing in a subset of donors that cross-reactive responses ex vivo 
correlated well with cross-reactive responses in T cell lines.
In summary, using the first full-breadth analysis of T 
cell responses to JEV in humans, we have demonstrated that 
a high quality IFN-γ–dominated CD4+ T cell response is 
associated with good recovery from JE in humans. JEV T 
cell responses are dominated by broadly cross-reactive CD8+ 
T cells in most healthy JEV-exposed donors. Cross-reactive 
responses in recovered JE patients, however, are much less 
frequent, though uncertainty remains regarding the true 
significance of this finding. In much of South and South-
east Asia, where JEV and DENV cocirculate, the effect of 
JEV immune responses could be significant in subsequent 
natural infection and in response to vaccines. Therefore, 
the sequence and timing of flavivirus infections and their 
Figure 7. Peptide epitopes of JEV identified in healthy JEV-exposed donors, recovered JE patients, and DENV-exposed donors. (A–C) Peptides 
were identified in ICS assays of short-term T cell lines expanded with peptide pools showing ex vivo responses or by ex vivo ELI SPOT. Both peptides that 
have been mapped down to the minimal epitope (eight peptides) and library peptides of 15–18 amino acids are shown. CD4+ responses are green, and 
CD8+ responses are blue. Location of peptide responses in healthy JEV-exposed donors (A), recovered JE patients (B), and two subjects reporting dengue 
illness (C) are shown. Three peptides in common between JE patients and either healthy group are marked by dotted lines. (D) Shannon entropy (H index) 
was calculated using all the available DENV and JEV complete polyprotein sequences from India (13 DENV1 sequences, 10 DENV2 sequences, 8 DENV3 
sequences, 5 DENV4 sequences, and 8 JEV sequences) and the sequences of the DENV1–4 and JEV peptide libraries used in this study. The H index varies 
from 0, corresponding to a single conserved amino acid residue at that position, to 4.322, where all 20 amino acids are represented equally. (E) Schematic 
representation of JEV proteins corresponding to their size. C, core protein. prM, pre-membrane protein. ENV, envelope protein. NS, non-structural protein. 
(F) The mean Shannon entropy of the flavivirus regions corresponding to 15 unique peptides identified in the healthy JEV-exposed group and 25 unique 
peptides identified in the recovered JE group (using the same virus polyprotein sequences as in D) was significantly lower in the epitopes identified from 
recovered JE patients (Mann Whitney U test). The bars depict the median and IQR, whiskers are 1.5 × IQR, and outliers are shown as points.
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Table 3. Variant peptides eliciting T cell responses
JEV peptide sequence Subject type Viruses with identical 
sequence
Subset Variant Virus/BEI peptide 
location
CSA VPV DW H DENV1 CD8 CSSVPV DW MVEV
MTT EDM LQVW H CD8 MTT EDMLRVW JEV
MTT EDMLSVW DENV1
MTT EDMLTVW DENV2,3
MTT EDMLKVW DENV4
MTT EDMLEVW WNV, YFV
MTT EDMLDVW TBEV
ALR GLP VRY H ZIKV CD8 ALR GLPIRY WNV, DENV2,4
NLF VMD EAH FTD PAS IEA HFT DPA SIA ARG YI H DENV2,3 CD8 NYNMIIMDE AHF TDPA DENV1 NS3 p49
IMDE AHF TDP ASIARRG DENV1 NS3 p50
NYNLIIMDE AHF TDP ASI DENV2 NS3 p38
NYNLIIMDE AHF TDPA DENV3 NS3 p48
PNY NLIVMD EAH FTD DENV4 NS3 p49
LIVMD EAH FTDPSSVAA DENV4 NS3 p50
AHF TDPSSVAAR GYI ST DENV4 NS3 p51
TMA MTD TTP FGQ QRV FK H WNV CD4 + CD8 MVTQIAMT DTT PFG QQRa DENV1 NS5 p60
AMT DTT PFG QQR VFK EKa DENV2 NS5 p61
MVTQMAM TDT TPF GQQRa DENV3 NS5 p60
MVTQLAMT DTT PFG QQRa DENV4 NS5 p60
GEA AAI FMT H WNV, DENV1,3,4, ZIKV CD8 MGE AAA IFM TAT PPG SVb DENV1 NS3 p54, DENV3 
NS3 p52
VEM GEA AAI FMT ATP PGb DENV4 NS3 p54
TAV LAP TRV VAA EMA EAL H WNV CD8 NVRTLILAP TRV VASEM DENV1 NS3 p38
LRTLILAP TRV VAA EM DENV2 NS3 p30
TLILAP TRV VAA EMEEA DENV3 NS3 p38, DENV4 
NS3 p39
DVM CHA TL D WNV, MVEV, SLEV CD8 DLM CHA TF DENV1–4, ZIKV
DAM CHA TL YFV
AVH SDL SYW IES RYN DTW JE CD4 NLAIHSD LSY WIE SRL WNV NS1 p26
WIE SRY NDT WKL ERA VF JE CD4 RLNDT WKL ERA VLG EVK WNV NS1 p28
IESEKNETWKLARASFI DENV NS1 p36
KQS VVA LGS QEG GLH QAL JE CD4 HAT KQSVIALG SQEGALH WNV E p34
ALG SQEGALHQ ALA GAI WNV E p35
VVVLGS QEGAMHTALTG DENV1 E p44
HAK KQDVVVLGS QEGAMH DENV2 E p34
VLGS QEGAMHTALT GA DENV2 E p35
HAK KQEVVVLGS QEGAMH DENV3 E p35, DENV1b
VLGS QEGAMHTALT GA DENV3 E p36,
HAKRQDVTVLGS QEGAMH DENV4 E p36
VLGS QEGAMHSALA GA DENV4 E p37
HGT VVI ELS YSG SDG PCK JE CD4 HGT VVLELQYTGTDGP CK WNV E p44
LGK AFS TTL KGA QRL AAL JE CD4 HKS GSSIGKAFTTTL KGA WNV E p55
KAFTTTL KGA QRL AAL WNV E p56
WDF GSI GGV FNS IGK AV JE CD4 WDF GSVGGVFTSVGKA VH WNV E p59
GVF NSI GKA VHQ VFG GAF VFTSVGKA VHQ VFG GAFR WNV E p60
AIS GDD CVV KPL DDR FCV VKP LDD RFA TAL HFL JE CD4 + CD8 AVSGD DCV VKP LDD RFA WNV NS5 p91+92c
VVK PLD DRF ATSLHF LNA
ISG DDC VVKPIDDR FAT DENV1 NS5 p115+116c
VVKPIDDR FAT ALTALN
ISG DDC VVK PLD DRFA DENV2 NS5 p116+117c
CVV KPL DDR FASALTAL
MAI SGD DCV VKP IDD RF DENV3 NS5 p115+116c
DCV VKPIDDR FANALLA
MAI SGD DCV VKP LDE RF DENV4 NS5 p116+117c
DCV VKP LDERFSTSLLF
JE, recovered JE patient; H, healthy JEV exposed; D, dengue exposed; MVEV, Murray Valley encephalitis virus; YFV, yellow fever virus; TBEV, tick-borne encephalitis virus; SLEV, St. Louis 
encephalitis virus; ZIKV, Zika virus. Variant peptides were synthesized or obtained from BEI resources; and their location within each peptide set (see Materials and methods) is given in the 
last column. Bold/underlined amino acids represent differences from the JEV sequence.
aLikely to represent conserved epitope DTT PFG QQR (see Fig. 2 D). 
bIdentical viral sequences, but corresponding peptides vary slightly. 
cPairs of peptides tested together in the same assay.
1347JEM Vol. 213, No. 7
effect on immunopathogenesis and potentially vaccine re-
sponses are worthy of further study. In the context of the 
current outbreak of Zika virus, this cross-reactivity at the T 
cell level, as we have identified here, could be of relevance 
to disease pathogenesis.
MAT ERI ALS AND MET HODS
Setting. The study was conducted at the Indian Institute of 
Science (IISc) and National Institute of Mental Health and 
Neurosciences (NIM HANS) in Bangalore and at VIMS, Bel-
lary (all in Karanataka State, India). Karnataka is endemic for 
JE; the disease occurs in rural areas but is uncommon in dis-
tricts around Bangalore. Recovered JE patients were therefore 
recruited at the VIMS medical center. For most experiments, 
blood samples were transported overnight by train for pro-
cessing in a laboratory in Bangalore.
Study subjects. Healthy donors with no history of neuro-
logical illness were recruited at IISc, NIM HANS, and VIMS. 
Recovered JE patients were recruited at dedicated outpa-
tient clinics held at the VIMS medical center. Healthy do-
nors were taken from family members of patients and other 
members of the local community. JE patients were drawn 
from previous cohorts studied in this location (Lewthwaite 
et al., 2010b,c) and recruited based on hospital records of 
positive CSF JEV IgM samples and follow-up of acute JE 
cases recruited during the study period (October 2011 to 
March 2013). All recovered JE patients had been admitted to 
the VIMS medical center with a clinical illness compatible 
with encephalitis (fever plus one of the following: clouding 
of consciousness, seizures, or focal neurological signs) and a 
positive ELI SA for JEV IgM in CSF. Patients had been ad-
mitted a median of 6 yr earlier (mean of 5.98 and range of 
6 mo to 14 yr). A small cohort was also recruited in the UK. 
Age, sex, travel history/previous area of residence, flavivirus 
vaccine history, and medical history (focused on flavivirus 
illness) were collected from all participants. Recovered JE 
patients underwent detailed neurological examination and 
disability assessment using the Liverpool outcome score 
(Lewthwaite et al., 2010a).
Ethics statement. This study was performed in accordance 
with the principles of the declaration of Helsinki. The ex-
perimental studies in India were approved by the IISc Insti-
tutional Human Ethics Committee (ref 5/2011). All Indian 
studies were also approved by the Liverpool School of Trop-
ical Medicine research ethics committee (ref 10.59). The 
component of the study conducted at the VIMS medical 
center was further reviewed by the VIMS ethics committee. 
The UK setup phase of the study was approved by the Na-
tional Research Ethics Committees Northwest 7 (ref 10/
H1008/23). All participants gave informed consent, or their 
parent/guardian gave consent if aged under 18. Minors age 
12–18 were able to give assent in addition to the guardian’s 
consent if they wished.
Peptide libraries. All available JEV complete genome se-
quences in the NCBI nucleotide database were downloaded 
in April 2010. Open reading frames were translated and 
aligned, and a consensus amino acid sequence was generated 
using Se-AL carbon (v2.0a11). Because only JEV genotype 
III was identified as circulating in South India until April 
2010, the sequence used for the JEV peptide library was the 
consensus sequence of JEV genotype III. However, genotype 
III sequences predominated in the database, and a consen-
sus sequence generated using all the available sequences was 
identical. The JEV consensus sequence was used to generate 
a library of peptides 18 amino acids long overlapping by 10. 
In addition, if the C-terminal amino acid residue of the pep-
tide was not an HLA class I anchor residue, the peptide was 
truncated until an “allowed” residue was reached or until a 
length of 15 amino acids (the overlap was kept constant at 
10) to improve the sensitivity for CD8+ responses (Draenert 
et al., 2003, 2004). Peptides were synthesized by Mimo-
topes Ltd. as a PepSet (Table S1). Peptides were dissolved in 
DMSO and pooled as indicated. The following peptide sets 
were obtained through Biodefense and Emerging Infection 
Resources, the National Institute of Allergy and Infectious 
Diseases, and the National Institutes of Health: DENV1 
Singapore/S275/1990 E (NR4551), NS1 (NR2751), NS3 
(NR2752), NS5 (NR4203); DENV2 New Guinea C (NGC), 
C (NR505), prM (NR506), E (NR507), NS1 (NR508), 
NS2a (NR2747), NS2b (NR2748), NS3 (NR509), NS4a 
(NR2749), NS4b (NR2750), NS5 (NR2746); DENV3 
Sleman 1978 E (NR511), DENV3 Philippines/H87/1956 
NS1 (NR2753), NS3 (NR2754), NS5 (NR4204); DENV4 
Dominica/814669/1981 E (NR512), DENV4 Singa-
pore/8976/1995 NS1 (NR2755), NS3 (NR2756), NS5 
(NR4205); WNV NY99-flamingo382-99 C (NR432), prM 
(NR433), M (NR434), E (NR435), NS1 (NR436), NS2a 
(NR437), NS2b (NR438), NS3 (NR439), NS4a (NR440), 
NS4b (NR441), and NS5 (NR442). Biodefense and Emerg-
ing Infection Resources peptides were dissolved using the 
same strategy as for JEV.
IFN-γ ELI SPOT assay. ELI SPOT assays were performed 
using anti–human IFN-γ capture and biotinylated detection 
antibodies from Mabtech according to the manufacturer’s 
instructions. Development was by detection with goat anti-
biotin-HRP and nitro-blue tetrazolium/BCIP 1-Step sub-
strate (Thermo Fisher Scientific). PBMCs were plated at 2 
× 105 per well and incubated overnight in 100 µl RPMI 
supplemented with 2 mM l-glutamine, 100 U/ml penicil-
lin, and 0.1 mg/ml streptomycin with 10% FCS (R10) and 
peptides at a final concentration of 3–6 µg/ml. The positive 
control was concanavalin A at a final concentration of 5 µg/
ml, and the negative control was DMSO at an equivalent 
concentration to the peptide pools.
ELI SPOT assays were considered positive if there were 
at least 50 spot-forming cells/106 PBMC and double the 
background value. In cases close to the cut-off value, confir-
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mation by another assay or mapping to a peptide was used. In 
seven JEV antibody–negative UK residents, no subject gave a 
response using these criteria, and studies on other members 
of the family Flaviviridae have used similar/identical thresh-
olds (Appanna et al., 2007; Parsons et al., 2008; Barnes et al., 
2012). Healthy donors were screened using 11 pools of pep-
tides (one pool for C/prM, two for E, one each for NS1 
and NS2, two for NS3, one for NS4, and three for NS5). 
Recovered JE patients, where available samples were smaller, 
were screened using six pools as indicated in Fig. 1 (A–C). 
For the healthy donors, responses to adjacent pools that were 
above the threshold were summed to create data comparative 
with the six pools used in recovered JE patients. Pools that 
did not reach the cut-off value were considered to be zero 
to prevent the creation of apparent responses by addition of 
two subthreshold values.
CFSE labeling and proliferation assays. PBMCs were used 
fresh or thawed and rested overnight. 8–10 million PBMCs 
were labeled with CFSE (Molecular Probes and Thermo 
Fisher Scientific) at a concentration of 1 µM in 1 ml of pre-
warmed PBS in the dark at 37°C for 10 min. Labeling was 
terminated by addition of five volumes of ice-cold R10 fol-
lowed by incubation on ice for 3–4 min. Labeled cells were 
washed twice and then plated at 0.5 million cells per well in 
250 µl streptomycin RPMI with 10% human serum (Valley 
Biomedical) and stimulated with peptide pools at a final con-
centration of 3 µg/ml. The positive control was concanavalin 
A at a final concentration of 2.5 µg/ml, and the negative con-
trol was DMSO at an equivalent concentration to the peptide 
pools. Cells were incubated for 8 d with removal and replace-
ment of 75 µl of medium for cytokine assay after 48 h and 5 d. 
After incubation, the cells were stained with near infrared 
(IR) cell viability marker (Molecular Probes and Thermo 
Fisher Scientific), fixed in 2% formaldehyde in PBS, and then 
frozen at −80°C in 1% BSA and 10% DMSO in PBS until 
analysis by flow cytometry. Before analysis, the cells were 
stained with CD3 Alexa Fluor 700 (clone UCHT-1), CD4 
PE (clone RPA-T4), CD8 APC (clone RPA-T8), and CD38 
PE-Cy7 (clone HIT2; all from BD). Responses were consid-
ered positive if there were at least 1% of cells in the CD4+ or 
CD8+ gates were CFSElo/CD38hi and this value was at 
least double the background.
Ex vivo peptide stimulation and ICS. WB was stimulated with 
JEV peptide pools in the presence of 10 µg/ml brefeldin A 
(Sigma-Aldrich) and incubated for 6  h in a water bath at 
37°C using the field-suitable method of Hanekom et al. 
(2004) that does not require a CO2 incubator. Power inter-
ruptions were frequent at VIMS, but the ambient temperature 
was 34–35°C, so the water bath maintained 36°C, within the 
normal range of human body temperature (Mackowiak et 
al., 1992). After 6 h, the stimulation was stopped by placing 
the tubes on ice followed by transport back to Bangalore the 
same night. Subjects studied in Bangalore followed an iden-
tical protocol with a 6-h stimulation terminated by placing 
the samples at 4°C overnight. Red blood cells were lysed the 
morning after. Freshly isolated PBMCs were stimulated with 
peptides overnight, and 10 µg/ml brefeldin A was added after 
1 h. 25 ng/ml PMA and 250 ng/ml ionomycin (Sigma-Al-
drich) served as the positive control; the negative control was 
the equivalent concentration of DMSO to the peptide pools. 
Cells stimulated by either method were stained with near IR 
cell viability marker and then fixed and cryopreserved pend-
ing analysis. Cells were permeabilized (Perm/Wash; BD) and 
stained with CD3 (clone UCHT-1), CD4 (clone RPA-T4), 
CD8 (clone RPA-T8), IFN-γ (clone 4S.B3), TNF-α (clone 
MAb11), IL2 (clone 5344.111), MIP-1β (clone D21-1351), 
and CD14 APC-Cy7 (clone MϕP9, dump channel). In some 
experiments, CD107a (clone H4A3) was added at the start of 
the stimulation to assess for degranulation (Betts et al., 2003). 
Anti–MIP-1β was from R&D Systems, and all other antibod-
ies were from BD. Cells were acquired on a cytometer (Canto 
II; BD) with photomultiplier tube voltages set using a single 
batch of setup and tracking beads (BD) throughout. Data were 
analyzed using FlowJo (v8.8.6; Tree Star), and polyfunctional 
T cell distributions were analyzed and presented using Simpli-
fied Presentation of Incredibly Complex Evaluations (SPI CE) 
software (v5.35), with preprocessing in Pestle (v1.7; Roederer 
et al., 2011). The SPI CE statistical function compare pies was 
used for comparison of T cell function patterns (Fig. 6 C).
WB ICS responses were considered positive if the re-
sponding population was ≥0.02% of the parent gate and dou-
ble the background (example data are given in Fig. 2 A). The 
background was subtracted before analysis.
Expansion of short-term T cell lines. Short-term T cell lines 
were expanded to JEV peptide pools or individual peptides 
showing ex vivo responses. Fresh or frozen rested PBMCs 
were stimulated with peptide pools at 3 µg/ml (up to a max-
imum of 1% DMSO). Where responding peptides were 
known, 10 µg/ml peptide was used to expand cells for 
cross-reactivity assays. Cells were cultured at two million cells 
per well in 24-well plates in 1 ml RPMI with 10% human 
serum, 10% natural T cell growth factor/IL2 (T-stim; Helvetica 
Health Care), and 20 ng/ml IL7 (R&D Systems) for 8–10 d. 
Before assay, the cells were rested overnight in R10 and then 
stimulated with peptides or pools of peptides for 6 h in the 
presence of brefeldin A. Cells were fixed, permeabilized, 
stained, and analyzed by flow cytometry by the same 
methods as ex vivo ICS.
Cytotoxicity assay. Cytotoxicity assays were conducted as 
previously described (Kurioka et al., 2015). In brief, appro-
priately HLA-matched peptide-loaded B cell lines were used 
as target cells and labeled with CFSE according to the manu-
facturer’s protocol. Cells were pulsed with peptide at the in-
dicated concentrations for 1 h followed by three washes with 
R10. Nonpeptide-pulsed cells were labeled with Cell Trace 
violet (CTV; Molecular Probes). Pulsed and unpulsed cells 
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were mixed in a 1:1 ratio and incubated with peptide-specific 
short-term T cell lines for 4 h at an effector/target ratio of 10:1 
in duplicates. CD107a (clone H4A3) was added at the start 
of the stimulation. After incubation, cells were stained with 
near IR viability marker, CD3 (clone UCHT1; eBioscience), 
CD8 (clone RPA-T8; eBioscience), and CD19 (clone LT19; 
Miltenyi Biotec). The mean percent survival of CFSE-labeled 
cells in wells containing no effectors was used to calculate the 
expected frequency of target cells in each well: expected ratio 
(ER) was calculated as %CFSE+/%CTV+. The specific killing 
was then calculated as: % Specific killing = 100 × [(ER × 
%CTV+ cells) − %CFSE+ cells]/(ER × %CTV+ cells).
HLA typing. HLA typing was done using commercially avail-
able kits at the TTK Rotary blood bank(Bangalore, India) 
or the Churchill Hospital (Oxford, England, UK). Not 
all subjects in the cohort were HLA typed; typing focused 
on those subjects where peptides were mapped. HLA class 
I A and B and class II D-related typing was done on sub-
jects who showed predominantly CD4 responses, and HLA 
class I A, B, and C typing was done on those showing pre-
dominantly CD8 responses.
HLA class I peptide tetramers. HLA class I peptide tetramers 
were supplied by the National Institutes of Health Tetramer 
Core Facility. JEV peptide tetramers were labeled with PE, 
and variant peptide tetramers were labeled with APC. 
The reagents used were HLA B*58:01-MTT EDM 
LQVW-PE (JEV NS5 809–818), HLA B*58:01-MTT EDM 
LSVW-APC (DENV1 NS5 803–812), HLA B*58:01-MTT 
EDM LTVW-APC (DENV2/3 NS5 804–813), and HLA 
B*58:01-MTT EDM LEVW-APC (WNV NS5 808–817). 
Fresh viable PBMCs or T cell lines were stained for 30 min 
at 37°C before being stained with cell viability maker and 
other surface antibodies as described in the Ex vivo peptide 
stimulation and ICS section. Cells were fixed before analysis 
on a cytometer (LSR II; BD).
Bead array. Supernatants collected from proliferation assays 
on day 2 and day 5 were assayed using a human cytokine/
chemokine kit (Bio-Plex 14-plex; Bio-Rad Laboratories) on 
the Bio-Plex 200 platform according to the manufacturer’s 
instructions. Supernatants were selected on the basis of the 
largest proliferation responses per subject. Responses were 
considered positive if the value secreted was at least double 
the amount detected from unstimulated cells, and the back-
ground was subtracted before analysis.
Viruses and cell lines. JEV 0423 (derived from SA14-14-2), 
DENV1 16007, DENV2 16681, DENV3 16562, DENV4 
C0036/06 and C6/36, and LLC-MK2 cells for use in PRNT50 
determination were supplied by the Armed Forces Research 
Institute of Medical Science virology department. JEV 
P20778, used for screening assays, and PS cells were grown in 
house at NIM HANS. LLC-MK2 cells were maintained in 
M199 medium, and C6/36 and PS cells were maintained in 
MEM. All media were supplemented with 2  mM l-gluta-
mine, 10% FCS, and 100 U/0.1 mg/ml penicillin/streptomy-
cin. LLC-MK2 cells and PS cells were maintained at 37°C 
with 5% CO2, and C6/36 cells were maintained at 28°C with 
5% CO2. All viruses were passaged once before use in C6/36 
cells, titered, and stored in aliquots at −80°C. Epstein-Barr 
virus–transformed HLA type B cell lines for HLA restriction 
experiments were provided by P. Goulder (University of Ox-
ford, Oxford, England, UK).
PRNTs. The sera of healthy donors were screened for JEV 
NAbs by incubating twofold dilutions down to 1 in 16 of 
heat-inactivated sera with 100 PFUs of JEV P20778 for 1 h at 
37°C. The mixtures were inoculated onto monolayers of PS 
cells with rocking at 37°C for 1 h to allow virus adsorption 
followed by removal of inoculum and addition of MEM with 
2% FCS and 1% low melting point agarose. After 3 d, destruc-
tion of the monolayer was assessed by crystal violet staining 
after fixing with 10% formalin in saline for 30 min. PRNT50 
were subsequently assayed in a subset by a standard method 
(Russell et al., 1967). In brief, heat-inactivated sera were di-
luted serially fourfold from 1 in 10 to 1 in 2,650, incubated 
with 30–50 PFUs of JEV or DENV1–4 at 37°C for 1 h, and 
then inoculated onto duplicate monolayers of LLC-MK2 cells 
with rocking at room temperature (25–28°C) for 1  h fol-
lowed by removal of inoculum and addition of 1 ml phenol 
red-free overlay medium with 0.9% low melting point aga-
rose. Plates were incubated for 4 d (JEV, DENV1, and 
DENV3), 6 d (DENV4), or 7 d (DENV2) before addition of 
a further 1 ml of overlay medium containing 4% neutral red. 
Plaques were visualized and counted after a further 24-h in-
cubation. PRNT50 was calculated by probit regression.
Statistical and bioinformatic methods. All statistical analyses 
were done using R version 3.1.2. Differences between non-
parametric unpaired variables were assessed with a two-sided 
Mann Whitney U (Wilcoxon rank sum) test. Categorical 
variables across groups were assessed by Fisher’s exact test. 
Correlations between ex vivo and in vitro expanded T cell 
responses were assessed by Spearman’s test. P-values <0.05 
were considered significant. The Shannon entropy of aligned 
JEV and DENV polyprotein sequences was calculated using 
the protein variability server of the Immunomedicine Group 
(Universidad Complutense, Madrid; Garcia-Boronat et al., 
2008). Sequence data were obtained from the National Insti-
tute of Allergy and Infectious Diseases Virus Pathogen Data-
base and Analysis Resource online by searching for all JEV 
and DENV complete genomes restricted to India as the 
country of origin (Pickett et al., 2012). The polyprotein se-
quences of the JEV and Biodefense and Emerging Infection 
Resources DENV1–4 peptide libraries used were also in-
cluded. Nucleic acid sequences were downloaded, edited to 
remove 5′ and 3′ untranslated regions, and translated using 
SeaView v4.4.2 (Gouy et al., 2010). Polyprotein alignments 
T cells in Japanese encephalitis | Turtle et al.1350
were performed using ClustalW (Larkin et al., 2007). HLA–
peptide binding predictions were conducted using the soft-
ware of the Bioinformatics and Molecular Analysis section of 
National Institutes of Health, SYF PEI THI, and HLArestric-
tor 1.2 server (Parker et al., 1994; Rammensee et al., 1999; 
Erup Larsen et al., 2011).
Online supplemental material. Table S1 shows peptides that 
were synthesized by Mimotopes Ltd. as a PepSet. Online 
supplemental material is available at http ://www .jem .org /cgi 
/content /full /jem .20151517 /DC1.
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